Pharmaceuticals
Pharma - API & CRAMS
from 592 today
We expect a CAGR of 19%/28%/25% in revenue/EBITDA/PAT over FY26-28. We value the stock at 35x FY28E EPS to arrive at our TP of INR720. We reiterate our BUY rating on the stock.
Blue Jet Healthcare shared a strong FY27 outlook, envisaging double-digit revenue growth in contrast media and pharma intermediate revenue crossing FY25's peak. We cut EPS by 9% for FY27E on RM inflation, revise TP to INR 680 as we raise FY28E P/E multiple to 35x, and retain BUY.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
